Introduction

Procedure for the preparation of a new anti-cachexia drug, consisting of the secretion of genetically modified muscle cells that also release microscopic vesicles capable of binding to the membrane of another muscle cell, activating its repair mechanism, demonstrated by the first in vitro tests included in the patent description.

Technical features

Procedure for the preparation of a new anti-cachexia drug, based on exosomes / nanoparticles, therefore innovative and customizable. On the market, there are no drugs for this clinical condition (to counteract muscle loss), but there are 17 molecules in the trial phase, of which only one is in phase 3. The present invention consists of the secretion of genetically modified muscle cells that release also microscopic vesicles able to bind to the membrane of another muscle cell activating its repair mechanism, demonstrated by the first in vitro tests. The bioactive substance is in fact constituted by the secretion of mouse muscle cells engineered with a plasmid that over-expresses one of the isoforms of the HPS60 heat shock protein. The product does not contain recombinant DNA, and induces a specific effect on mouse muscle cells. This method can be easily transferred to humans. The nanoparticles can recognise the target cell. The TRL of the invention is 4 (technology validated in the laboratory).

Possible Applications

• Anti-cachectic products that act directly on muscle mass.

Advantages

• The product is not a hormone;
• The effects are targeted to skeletal muscle;
• The product produces an Increase in body weight;
• The product improves patient mobility;
• The product increases muscle strength;
• Raw production materials available at market cost.